21세기 다발골수종의 단일 기관 현실 세계 경험
Single-Center Real-World Experience of Multiple Myeloma in the 21st Century
3
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: The incidence of multiple myeloma (MM) in Korea is rapidly increasing. The diagnostic criteria of MM have been updated and novel therapeutic agents are available. This study explored the features of MM patients registered at Asan Medical Center (AMC) and the outcomes over the past 15 years. Methods: Data were obtained from the AMC MM registry, which has been collecting the data of MM patients prospectively. The 774 MM patients included in our analysis were diagnosed from 2003, when thalidomide became available as a novel therapeutic agent, until April 2019. The 2-year survival rate of these patients was assessed. Patients were divided into two groups based on whether they were older or younger than 65 years, which is the cutoff age for the indication of autologous stem cell transplantation. Patients were also grouped according to the year of diagnosis: up to 2006, when bortezomib became available, and up to 2010, when the cost of lenalidomide was reimbursed. Results: Patients < 65 years of age had better prognostic features, including a better performance, less advanced disease stage, and fewer abnormalities in their fluorescent in-situ hybridization (FISH) analysis results. A comparison of our Korean patients with patients registered in the Myeloma Related Disorder Registry data of Australia and New Zealand, showed ethnic discrepancies. The median overall survival of all patients was 3.7 years, with a 5-year survival rate of 41.8% and a 10-year survival rate of 23.4%. Survival progressively improved in patients diagnosed later. Age, performance status, renal function, C-reactive protein level, lactate dehydrogenase level, and cytogenetic findings were identified as significant prognostic factors. Conclusions: This real-world survey revealed the clinical features and survival rates of patients at a tertiary Korean Hospital who were diagnosed with MM at the beginning of 21st century.
Abstract
Background/Aims: The incidence of multiple myeloma (MM) in Korea is rapidly increasing. The diagnostic criteria of MM have been updated and novel therapeutic agents are available. This study explored the features of MM patients registered at Asan Medical Center (AMC) and the outcomes over the past 15 years. Methods: Data were obtained from the AMC MM registry, which has been collecting the data of MM patients prospectively. The 774 MM patients included in our analysis were diagnosed from 2003, when thalidomide became available as a novel therapeutic agent, until April 2019. The 2-year survival rate of these patients was assessed. Patients were divided into two groups based on whether they were older or younger than 65 years, which is the cutoff age for the indication of autologous stem cell transplantation. Patients were also grouped according to the year of diagnosis: up to 2006, when bortezomib became available, and up to 2010, when the cost of lenalidomide was reimbursed. Results: Patients < 65 years of age had better prognostic features, including a better performance, less advanced disease stage, and fewer abnormalities in their fluorescent in-situ hybridization (FISH) analysis results. A comparison of our Korean patients with patients registered in the Myeloma Related Disorder Registry data of Australia and New Zealand, showed ethnic discrepancies. The median overall survival of all patients was 3.7 years, with a 5-year survival rate of 41.8% and a 10-year survival rate of 23.4%. Survival progressively improved in patients diagnosed later. Age, performance status, renal function, C-reactive protein level, lactate dehydrogenase level, and cytogenetic findings were identified as significant prognostic factors. Conclusions: This real-world survey revealed the clinical features and survival rates of patients at a tertiary Korean Hospital who were diagnosed with MM at the beginning of 21st century.
참고문헌 (27)
- Junshik Hong, "Recent advances in multiple myeloma: a Korean perspective", The Korean Journal of Internal Medicine, 31(5), pp.820~834 (2016), 대한내과학회[DOI]
- 홍세리, "Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2018", Cancer Research and Treatment, 53(2), pp.301~315 (2021), 대한암학회[DOI]
- 정성훈, "Frontline therapy for newly diagnosed patients with multiple myeloma", Blood Research, 55, pp.37~42 (2020), 대한혈액학회[DOI]
- 이지현, "Treatment of relapsed and refractory multiple myeloma", Blood Research, 55, pp.43~53 (2020), 대한혈액학회[DOI]
- Kim SJ, "Clinical features and survival outcomes in patients with multiple myeloma : analysis of web-based data from the Korean Myeloma Registry", Acta Haematol, 122, pp.200~210 (2009)
- Song HH, "Prognostic factors affecting response to chemotherapy and survival duration in Korean patients with multiple myeloma", Korean J Med, 58, pp.83~91 (2000)
- International Myeloma Working Group, "Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group", Br J Haematol, 121, pp.749~757 (2003)
- Rajkumar SV, "International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma", Lancet Oncol, 15, pp.e538~e548 (2014)[DOI]
- Greipp PR, "International staging system for multiple myeloma", J Clin Oncol, 23, pp.3412~3420 (2005)
- Palumbo A, "Revised international staging system for multiple myeloma : a report from International Myeloma Working Group", J Clin Oncol, 33, pp.2863~2869 (2015)
- Kumar S, "International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma", Lancet Oncol, 17, pp.e328~e346 (2016)[DOI]
- Bergin K, "The myeloma landscape in Australia and New Zealand: the first 8 years of the Myeloma and Related Diseases Registry (MRDR)", Clin Lymphoma Myeloma Leuk, 21, pp.e510~e520 (2021)[DOI]
- Kazandjian D, "Multiple myeloma epidemiology and survival : a unique malignancy", Semin Oncol, 43, pp.676~681 (2016)
- Kumar SK, "Multiple myeloma", Nat Rev Dis Primers, 3, pp.17046~ (2017)
- 방수미, "High Dose Therapy Followed by Autologous Peripheral Blood Stem Cell Transplantation as a First Line Treatment for Multiple Myeloma: a Korean Multicenter Study", Journal of Korean Medical Science, 18(5), pp.673~678 (2003), 대한의학회
- Jae-LyunLee, "The Efficacy of High-dose Melphalan with Autologous Peripheral Blood Stem Cell Transplantation in Patients with Multiple Myeloma", Yonsei Medical Journal, 44(5), pp.800~810 (2003), 연세대학교의과대학
- 고옥배, "Double Autologous Stem Cell Transplantation for Multiple Myeloma: A Korean Single Center Study", The Korean Journal of Internal Medicine, 20(3), pp.237~242 (2005), 대한내과학회
- 이재훈, "한국인 다발성 골수종의 역학 변화", Blood Research, 41(4), pp.1~1 (2006), 대한혈액학회
- Kim H, "New staging systems can predict prognosis of multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation as first-line therapy", Biol Blood Marrow Transplant, 12, pp.837~844 (2006)
- 정용필, "Poor Outcomes for IgD Multiple Myeloma Patients Following High-Dose Melphalan and Autologous Stem Cell Transplantation: A Single Center Experience", Journal of Korean Medical Science, 23(5), pp.819~824 (2008), 대한의학회
- Kim JS, "Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation", Biol Blood Marrow Transplant, 15, pp.463~470 (2009)
- Kim JE, "Serum albumin level is a significant prognostic factor reflecting disease severity in symptomatic multiple myeloma", Ann Hematol, 89, pp.391~397 (2010)
- Lee JH, "Multiple myeloma in Korea:past, present, and future perspectives. Experience of the Korean Multiple Myeloma Working Party", Int J Hematol, 92, pp.52~57 (2010)
- Kim MK, "Immunoglobulin D multiple myeloma : response to therapy, survival, and prognostic factors in 75 patients", Ann Oncol, 22, pp.411~416 (2011)
- Jo JC, "Initial cytoreductive treatment with thalidomide plus bolus vincristine", doxorubicin and reduced dexamethasone followed by autologous stem cell transplantation for multiple myeloma, 2011, pp.29, 175~181
- Kang J, "Efficacy and survival outcome associated with the use of novel agents and autologous stem cell transplantation in cases of immunoglobulin D multiple myeloma in Korea", Acta Haematol, 139, pp.185~192 (2018)
- 조형우, "림프종과 골수종 환자에서 자가 조혈모세포 이식술의 현실 세계 경험", 대한내과학회지, 96(6), pp.501~511 (2021), 대한내과학회[DOI]